This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Exploratory Study of OPC-12759 Ophthalmic Suspension

This study has been completed.
Information provided by (Responsible Party):
Otsuka Pharmaceutical Co., Ltd. Identifier:
First received: December 13, 2011
Last updated: February 19, 2015
Last verified: February 2015
The purpose of this study is to evaluate the efficacy of OPC-12759 ophthalmic suspension for patients with keratoconjunctival epithelial disorder compared with sodium hyaluronate. Also, safety of OPC-12759 is to be assessed.

Condition Intervention Phase
Keratoconjunctival Epithelial Disorder Drug: OPC-12759 ophthalmic suspension Drug: Sodium hyaluronate ophthalmic solution Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Exploratory Study of OPC-12759 Ophthalmic Suspension in Patients With Keratoconjunctiva Epithelial Disorder

Resource links provided by NLM:

Further study details as provided by Otsuka Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • Change in the Keratoconjunctival Staining Score From Baseline [ Time Frame: Basekine, 4 weeks ]

    Keratoconjunctival staining indicates the damage to the corneal and conjunctival epithelium. The cornea and conjunctiva were divided into 3 and 2 fractions, respectively, each of which was given a staining score from 0 to 3, and the total score was calculated (0-15). 0 is better.

    The change from baseline at the end of instillation (LOCF) in the keratoconjunctival staining score were compared between the 2% rebamipide group and the 0.1% sodium hyaluronate group using a t-test.

Enrollment: 102
Study Start Date: December 2011
Study Completion Date: December 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: OPC-12759 ophthalmic suspension
OPC-12759 ophthalmic suspension
Drug: OPC-12759 ophthalmic suspension
OPC-12759 ophthalmic suspension 2%
Active Comparator: Sodium hyaluronate ophthalmic solution
Sodium hyaluronate ophthalmic solution
Drug: Sodium hyaluronate ophthalmic solution
Sodium hyaluronate ophthalmic solution 0.1%


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of superficial punctate keratopathy, corneal erosion or persistent epithelial defect
  2. Fluorescein corneal staining score of 3 or higher

Exclusion Criteria:

  1. Active ocular infection
  2. Vernal keratoconjunctivitis
  3. Recurrent corneal erosion
  4. Physical irritation of eyelashes or relaxed bulbar conjunctiva to cornea or conjunctiva
  5. Subjects who cannot discontinue or anticipate use of eye drops except for limited concomitant ones during the study. Soft-santear is allowed during the screening period.
  6. Anticipated use of contact lens during the study.
  7. Insertion of punctal plug or fall out of punctal plug within 3 months
  8. Subjects who are judged by the investigator to be ineligible for the study because of a past or concurrent systemic disease.
  9. Receipt of any investigational product within 4 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01493180

Kanto region
Hachioji, Japan
Kansai region
Ibaraki, Japan
Kansai region
Ikoma, Japan
Kansai Region
Kobe, Japan
Chugoku region
Kure, Japan
Kansai region
Kyoto, Japan
Tokai region
Nagoya, Japan
Kansai region
Osakasayama, Japan
Kansai region
Osaka, Japan
Kanto region
Tokyo, Japan
Sponsors and Collaborators
Otsuka Pharmaceutical Co., Ltd.
Study Director: Eiji Murakami Division Dermatilogicals and Ophtalmolgicals, Otsuka Pharmaceutical Co., Ltd.
  More Information

Responsible Party: Otsuka Pharmaceutical Co., Ltd. Identifier: NCT01493180     History of Changes
Other Study ID Numbers: 037E-11-002
JapicCTI-111708 ( Other Identifier: Japic )
Study First Received: December 13, 2011
Results First Received: January 17, 2014
Last Updated: February 19, 2015

Additional relevant MeSH terms:
Pharmaceutical Solutions
Ophthalmic Solutions
Hyaluronic Acid
Anti-Ulcer Agents
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Enzyme Inhibitors
Adjuvants, Immunologic
Immunologic Factors
Viscosupplements processed this record on June 22, 2017